Viking TherapeuticsVKTX
VKTX
0
Funds holding %
of 7,398 funds
0
Analysts bullish %
of 7 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
80% more call options, than puts
Call options by funds: $296M | Put options by funds: $164M
13% more repeat investments, than reductions
Existing positions increased: 144 | Existing positions reduced: 127
7% less first-time investments, than exits
New positions opened: 80 | Existing positions closed: 86
3.0% less ownership
Funds ownership: 76.5% [Q3] → 73.5% (-3.0%) [Q4]
4% less funds holding
Funds holding: 418 [Q3] → 403 (-15) [Q4]
38% less capital invested
Capital invested by funds: $5.3B [Q3] → $3.3B (-$2.01B) [Q4]
75% less funds holding in top 10
Funds holding in top 10: 8 [Q3] → 2 (-6) [Q4]
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$38
59%
upside
Avg. target
$86
261%
upside
High target
$125
423%
upside
7 analyst ratings
6 positive
86%
1 neutral
14%
0 negative
0%
HC Wainwright & Co. Joseph Pantginis 20% 1-year accuracy 85 / 420 met price target | 327%upside $102 | Buy Reiterated | 26 Mar 2025 |
Scotiabank George Farmer 27% 1-year accuracy 6 / 22 met price target | 327%upside $102 | Sector Outperform Initiated | 13 Feb 2025 |
Citigroup David Lebowitz 32% 1-year accuracy 6 / 19 met price target | 59%upside $38 | Neutral Initiated | 7 Feb 2025 |
Maxim Group Naz Rahman 8% 1-year accuracy 1 / 12 met price target | 193%upside $70 | Buy Maintained | 7 Feb 2025 |
B. Riley Securities Mayank Mamtani 14% 1-year accuracy 3 / 22 met price target | 302%upside $96 | Buy Reiterated | 7 Feb 2025 |
Financial journalist opinion
Based on 26 articles about VKTX published over the past 30 days
Negative
Zacks Investment Research
3 hours ago
Viking Therapeutics, Inc. (VKTX) Stock Slides as Market Rises: Facts to Know Before You Trade
In the latest trading session, Viking Therapeutics, Inc. (VKTX) closed at $23.91, marking a -0.99% move from the previous day.
Positive
MarketBeat
1 day ago
Which Healthcare Stock Is the Best Buy Right Now?
In the world of upstart pharmaceuticals and healthcare companies, timing is everything. These firms often struggle for an extended period of time before becoming profitable, but when they see success with a new product—or even clinical trial results suggesting a new product could be on the horizon—they can experience huge rallies in a very short period of time.
Negative
Zacks Investment Research
5 days ago
Brokers Suggest Investing in Viking Therapeutics (VKTX): Read This Before Placing a Bet
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Neutral
Zacks Investment Research
5 days ago
VKTX Finishes Enrolment in Mid-Stage Study on Oral Weight-Loss Drug
Viking enrolls around 280 participants in the phase II study evaluating the oral version of its obesity drug. Data from this study is expected in 2H25.
Positive
Investors Business Daily
6 days ago
Viking Therapeutics Skids Despite 'Rapid' Enrollment In Obesity Pill Study
Viking Therapeutics stock skidded Wednesday despite the "encouraging" speed with which the company enrolled patients in an obesity study. The post Viking Therapeutics Skids Despite 'Rapid' Enrollment In Obesity Pill Study appeared first on Investor's Business Daily.
Neutral
PRNewsWire
6 days ago
Viking Therapeutics Announces Completion of Enrollment in Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity
13-Week Study Evaluating the Safety and Efficacy of Oral VK2735 Dosed Once Daily Results Expected in 2H25 SAN DIEGO , March 26, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the completion of subject enrollment in its Phase 2 clinical trial of the oral tablet formulation of VK2735, the company's dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. VK2375 is being developed in both oral and subcutaneous formulations for the potential treatment of various metabolic disorders such as obesity.
Neutral
Zacks Investment Research
1 week ago
Viking Therapeutics, Inc. (VKTX) Rises But Trails Market: What Investors Should Know
In the most recent trading session, Viking Therapeutics, Inc. (VKTX) closed at $29.28, indicating a +1.14% shift from the previous trading day.
Positive
The Motley Fool
1 week ago
Better Stock to Buy Right Now: Viking Therapeutics vs. Eli Lilly
It's hard to overstate how much demand could be out there for effective weight management drugs. The global anti-obesity drug market is expected to generate $12.8 billion in sales this year, and according to a new report from Research and Markets, sales could swell to $104.9 billion by 2035.
Positive
The Motley Fool
1 week ago
1 Biotech Stock Down 52% That Could Soar by 233%, According to Wall Street
Last year, Viking Therapeutics (VKTX 1.83%), a mid-cap biotech, attracted the market's attention thanks to excellent midstage clinical trial results. The company's shares soared in late February 2024, but, unfortunately, they have been southbound since then.
Positive
The Motley Fool
1 week ago
Down 65% From Its 52-Week High, Is Viking Therapeutics Stock a Bargain Buy?
Viking Therapeutics (VKTX -0.30%) is a promising growth stock with a strong GLP-1 drug candidate in VK2735, which may eventually rake in significant revenue from the anti-obesity market. It has demonstrated encouraging results in clinical trials; however, it isn't approved just yet.
Charts implemented using Lightweight Charts™